PureTech Health (PRTC) 2018年年度报告「LSE」.pdf

1、BRAIN IMMUNE GUTD E V E L O P I N GM E D I C I N E SPureTech Health plc Annual report and accounts 2018PureTech Health plc Annual report and accounts 2018 1Overview1 Group cash and short-term investments includes consolidated cash and short-term investments plus the cash and short-term investment po

2、sition of Independent Affiliates(resTORbio and Akili)which are not included in our consolidated statement of financial position.PureTech HealthPureTech Health,plc(HQ:Boston,MA;LSE:PRTC)(“PureTech Health”,“PureTech”or the“Company”)is an advanced biopharmaceutical company developing medicines for dysf

3、unctions of the Brain-Immune-Gut(BIG)axis across its affiliates and its own internal labs.The Companys focus is driven by deep insights into the connection amongst these three systems that make up the BIG axis and their resulting roles in diseases that have proven resistant to established therapeuti

4、c approaches.By harnessing this emerging field of human biology,PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.PureTechs entrepreneurial,non-binary,and capital-efficient innovation engine is led by ateam with aproven

5、track record of developing new therapeutics and building shareholder value.Together,this team has achieved numerous significant milestones by progressing therapeutic candidates through human proof-of-concept to regulatory clearance and forging strategic relationships with major pharmaceutical compan

6、ies,leading academic scientists and institutions.Dedicated to tackling some of the most important health issues facing society in order to improve patients lives and generate significant value for PureTechs shareholders,PureTech Health is pioneering new frontiers in medicine with:an impressive track